Trial Profile

Dendritic Cells loaded with allogeneic tumor lysate (MesoPher) in combination with a CD40 agonist (Mitazalimab) for metastatic pancreatic disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous dendritic cell vaccine Amphera (Primary) ; Autologous dendritic cell vaccine Amphera (Primary) ; Mitazalimab (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions
Acronyms REACtiVe-2

01 Dec 2025 Results presented in the Alligator Bioscience Media Release.
01 Dec 2025 According to an Alligator Bioscience media release, data from this study has been published in Nature communications.
25 Jul 2025 According to an Alligator Bioscience media release, company announces that data from this study will be presented at the European Society for Medical Oncology (ESMO) Congress 2025, taking place on 17-21 October in Berlin, Germany.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com